Trial Outcomes & Findings for Transcutaneous Electrical Acustimulation (TEA) for Gastroparesis (NCT NCT05362578)
NCT ID: NCT05362578
Last Updated: 2026-07-20
Results Overview
The American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptoms Index-Daily Diary (ANMS GCSI-DD) symptom daily score was generated by summing the scores on each of five symptom items (nausea, early satiety, postprandial fullness, upper abdominal pain, and number of vomiting episodes), each ranging from 0 (none) to 4 (very severe) and then dividing by 5, that is the number of items within the gastroparesis related symptom score. The minimum score was 0 and the maximum score was 4. Higher numbers indicated greater symptom impact. Scores will be compared from day 0 to day 84.
COMPLETED
NA
41 participants
Up to 84 days
2026-07-20
Participant Flow
Participant milestones
| Measure |
Treatment Group
Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
transcutaneous electrical accustimulation at treatment point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Sham Group
Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
transcutaneous electrical accustimulation at sham point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
|---|---|---|
|
Overall Study
STARTED
|
21
|
20
|
|
Overall Study
Sham Group Participants who opted to receive open-label treatment after 8 weeks.
|
0
|
13
|
|
Overall Study
COMPLETED
|
15
|
13
|
|
Overall Study
NOT COMPLETED
|
6
|
7
|
Reasons for withdrawal
| Measure |
Treatment Group
Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
transcutaneous electrical accustimulation at treatment point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Sham Group
Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
transcutaneous electrical accustimulation at sham point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
4
|
5
|
|
Overall Study
Lost to Follow-up
|
2
|
2
|
Baseline Characteristics
Transcutaneous Electrical Acustimulation (TEA) for Gastroparesis
Baseline characteristics by cohort
| Measure |
Treatment Group
n=21 Participants
Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
transcutaneous electrical accustimulation at treatment point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Sham Group
n=20 Participants
Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
transcutaneous electrical accustimulation at sham point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Total
n=41 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
50.429 years
STANDARD_DEVIATION 16.1387 • n=20 Participants
|
51.45 years
STANDARD_DEVIATION 12.7382 • n=20 Participants
|
50.9268 years
STANDARD_DEVIATION 14.4073 • n=40 Participants
|
|
Sex: Female, Male
Female
|
16 Participants
n=20 Participants
|
17 Participants
n=20 Participants
|
33 Participants
n=40 Participants
|
|
Sex: Female, Male
Male
|
5 Participants
n=20 Participants
|
3 Participants
n=20 Participants
|
8 Participants
n=40 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
21 Participants
n=20 Participants
|
20 Participants
n=20 Participants
|
41 Participants
n=40 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=20 Participants
|
2 Participants
n=20 Participants
|
2 Participants
n=40 Participants
|
|
Race (NIH/OMB)
White
|
21 Participants
n=20 Participants
|
18 Participants
n=20 Participants
|
39 Participants
n=40 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Region of Enrollment
United States
|
21 Participants
n=20 Participants
|
20 Participants
n=20 Participants
|
41 Participants
n=40 Participants
|
PRIMARY outcome
Timeframe: Up to 84 daysPopulation: Results data was only analyzed for participants who completed the follow up visit.
The American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptoms Index-Daily Diary (ANMS GCSI-DD) symptom daily score was generated by summing the scores on each of five symptom items (nausea, early satiety, postprandial fullness, upper abdominal pain, and number of vomiting episodes), each ranging from 0 (none) to 4 (very severe) and then dividing by 5, that is the number of items within the gastroparesis related symptom score. The minimum score was 0 and the maximum score was 4. Higher numbers indicated greater symptom impact. Scores will be compared from day 0 to day 84.
Outcome measures
| Measure |
Treatment Group
n=15 Participants
Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
transcutaneous electrical accustimulation at treatment point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Sham Group
n=12 Participants
Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
transcutaneous electrical accustimulation at sham point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
|---|---|---|
|
Change in American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptoms Index-Daily Diary (ANMS GCSI-DD)
Baseline
|
2.24 score on a scale
Standard Error 0.20
|
1.95 score on a scale
Standard Error 0.22
|
|
Change in American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptoms Index-Daily Diary (ANMS GCSI-DD)
Follow Up Visit
|
1.97 score on a scale
Standard Error 0.20
|
1.66 score on a scale
Standard Error 0.23
|
SECONDARY outcome
Timeframe: 8 weeksPopulation: Results data was only analyzed for participants who completed the Week 8 follow up. Because of a technical issue with the survey system, baseline data was not collected as intended, and there was no further attempt to collect it. Some participants submitted survey data at week 4 and week 8. Statistical analysis was only conducted for week 4 data, as there was an insufficient number of responses for analysis of week 8 data.
A 36-question assessment to score overall quality of life. The SF-36 consisted of eight health domains with questions, which were the weighted sums of the questions in their section. Each scale was directly transformed into a 0-100 scale on the assumption that each question carried equal weight. The scores from those domains were then averaged together for a final score within a full range of 0-100, with higher values indicating greater function and 100 representing the highest level of functioning possible.
Outcome measures
| Measure |
Treatment Group
n=16 Participants
Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
transcutaneous electrical accustimulation at treatment point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Sham Group
n=10 Participants
Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
transcutaneous electrical accustimulation at sham point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
|---|---|---|
|
36-Item Short Form Survey Instrument (SF-36) to Measure Quality of Life (QOL)
Week 4
|
43.4 score on a scale
Standard Deviation 7.8
|
56 score on a scale
Standard Deviation 9.4
|
|
36-Item Short Form Survey Instrument (SF-36) to Measure Quality of Life (QOL)
Week 8
|
38.5 score on a scale
Standard Deviation 9.91
|
52.5 score on a scale
Standard Deviation 17.5
|
SECONDARY outcome
Timeframe: 8 weeksPopulation: Results data was only analyzed for participants who completed the Week 8 follow up and participated in the water-satiety drink test.
A water-satiety drink test was performed during which the participant was asked to drink at a speed of 60ml/min until reaching the maximum tolerable volume (MTV). Results reflect the maximum tolerable volume of the water-satiety drinking test.
Outcome measures
| Measure |
Treatment Group
n=12 Participants
Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
transcutaneous electrical accustimulation at treatment point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Sham Group
n=11 Participants
Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
transcutaneous electrical accustimulation at sham point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
|---|---|---|
|
Gastric Accommodation
Baseline
|
605.64 mL
Standard Deviation 284.71
|
850 mL
Standard Deviation 359.26
|
|
Gastric Accommodation
8 Weeks
|
772.50 mL
Standard Deviation 393.79
|
731.18 mL
Standard Deviation 387.40
|
SECONDARY outcome
Timeframe: Visit 1 and visit 2 at 8 weeksPopulation: Results data was only analyzed for participants who completed the Week 8 follow up.
EGG was performed twice at both the baseline and at the 8-week visit. One 30-minute EGG was performed prior to the gastric accommodation test, and one 30-minute EGG was performed after the nutrient drink test. The goal was to measure gastric slow waves, which act as an indirect measure of gastric transit time. The difference in slow waves was compared pre- and post- gastric accommodation. Slow waves were also compared between visit 1 and visit 2. The percentage of normal gastric slow waves was previously used to predict delayed gastric emptying in participants with gastroparesis. Higher percentage of normal slow waves suggests an improvement in gastric emptying.
Outcome measures
| Measure |
Treatment Group
n=12 Participants
Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
transcutaneous electrical accustimulation at treatment point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Sham Group
n=11 Participants
Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
transcutaneous electrical accustimulation at sham point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
|---|---|---|
|
Electrogastrogram (EGG)
Baseline
|
52.04 percentage of normal slow waves
Standard Deviation 10.01
|
60.52 percentage of normal slow waves
Standard Deviation 14.68
|
|
Electrogastrogram (EGG)
8 Weeks
|
63.94 percentage of normal slow waves
Standard Deviation 14.95
|
61.12 percentage of normal slow waves
Standard Deviation 12.76
|
SECONDARY outcome
Timeframe: 8 weeksPopulation: Results data was only analyzed for participants who completed the Week 8 follow up and participated in the water-satiety drink test.
ECG recorded while sitting 30 minutes b/f drinking (fasting) and 30 minutes after drinking water. Same procedure used at first visit (pretreatment) and second visit (post-treatment week 8). Goal was to measure autonomic function by calculating heart rate variability (HRV). Artifacts from recoded ECG signal were removed and R-peaks were detected. Time interval b/w successive R-peaks (RR interval) was calculated to generate HRV signal, which was used to calculate HRV parameters. Power w/i 0.15-0.40 Hz frequency band was defined as high-frequency (HF) power, while power w/i 0.04-0.15 Hz band was defined as low-frequency (LF) power. Normalized high-frequency power (HFn) was calculated as HFn = HF/HF+LF. HFn showed vagal/parasympathetic activity, with higher values indicating more active parasympathetic response and more responsive autonomic system. Pre-drinking (fasting) value of each HRV parameter at baseline (week 0) was compared to week 8 (after treatment) for both TEA and Sham groups.
Outcome measures
| Measure |
Treatment Group
n=12 Participants
Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
transcutaneous electrical accustimulation at treatment point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Sham Group
n=11 Participants
Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
transcutaneous electrical accustimulation at sham point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
|---|---|---|
|
Electrocardiogram (ECG) - High-frequency Power (HFn)
Baseline
|
0.34 ratio
Standard Deviation 0.15
|
0.40 ratio
Standard Deviation 0.17
|
|
Electrocardiogram (ECG) - High-frequency Power (HFn)
Week 8
|
0.40 ratio
Standard Deviation 0.14
|
0.44 ratio
Standard Deviation 0.13
|
SECONDARY outcome
Timeframe: 8 weeksPopulation: Results data was only analyzed for participants who completed the Week 8 follow up and participated in the water-satiety drink test.
The ECG was recorded in sitting position for 30 minutes before drinking (under fasting state) and 30 minutes after drinking water in sitting position. The same procedure was followed during first visit (pretreatment) and during the second visit (post-treatment week 8). The goal is to measure autonomic function via calculating the heart rate variability (HRV). The artifacts from the recoded ECG signal were removed and R-peaks were detected. The time interval between successive R peaks (the RR interval) was calculated to generate the HRV signal, which was used to calculate the HRV parameters. Sympathetic Index (SI) is HRV marker of Sympathetic Nervous system activity, with lower number meaning lower sympathetic activity and high numbers indicating greater sympathetic activity. The pre-drinking (fasting) value of each HRV parameter at baseline (week 0) was compared to that at week 8 (after treatment) for both TEA and Sham groups.
Outcome measures
| Measure |
Treatment Group
n=12 Participants
Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
transcutaneous electrical accustimulation at treatment point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Sham Group
n=11 Participants
Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
transcutaneous electrical accustimulation at sham point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
|---|---|---|
|
Electrocardiogram (ECG) - Sympathetic Index (SI)
Baseline
|
122.93 s-2
Standard Deviation 110.85
|
145.17 s-2
Standard Deviation 104.45
|
|
Electrocardiogram (ECG) - Sympathetic Index (SI)
8 Week
|
189.27 s-2
Standard Deviation 215.08
|
143.10 s-2
Standard Deviation 98.93
|
SECONDARY outcome
Timeframe: 8 weeksPopulation: Results data was only analyzed for participants who completed the Week 8 follow up and participated in the water-satiety drink test.
The ECG was recorded in sitting position for 30 minutes before drinking (under fasting state) and 30 minutes after drinking water in sitting position. The same procedure was followed during first visit (pretreatment) and during the second visit (post-treatment week 8). The goal was to measure autonomic function via calculating the heart rate variability (HRV). The artifacts from the recoded ECG signal were removed and R-peaks were detected. The time interval between successive R peaks (the RR interval) was calculated to generate the HRV signal, which was used to calculate the HRV parameters. The LFn/HFn ratio reflects autonomic balance, with higher value indicating the autonomic balance shifts towards the sympathetic, which a lower value indicates that the autonomic balance shifts towards the parasympathetic. The pre-drinking (fasting) value of each HRV parameter at baseline (week 0) was compared to that at week 8 (after treatment) for both TEA and Sham groups.
Outcome measures
| Measure |
Treatment Group
n=12 Participants
Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
transcutaneous electrical accustimulation at treatment point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Sham Group
n=11 Participants
Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
transcutaneous electrical accustimulation at sham point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
|---|---|---|
|
Electrocardiogram (ECG) - LFn/HFn Ratio
Baseline
|
2.58 Ratio
Standard Deviation 1.66
|
1.99 Ratio
Standard Deviation 1.29
|
|
Electrocardiogram (ECG) - LFn/HFn Ratio
8 Week
|
1.59 Ratio
Standard Deviation 0.85
|
1.56 Ratio
Standard Deviation 1.03
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 12 weeksA 36 question assessment to score overall quality of life. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.
Outcome measures
Outcome data not reported
Adverse Events
Treatment Group
Sham Group
Participants Who Received Open Label Treatment After Having Received Sham
Serious adverse events
| Measure |
Treatment Group
n=21 participants at risk
Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
transcutaneous electrical accustimulation at treatment point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Sham Group
n=20 participants at risk
Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
transcutaneous electrical accustimulation at sham point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Participants Who Received Open Label Treatment After Having Received Sham
n=13 participants at risk
Participants in this arm were randomized into the sham group arm for the 8-week trial period. Following the trial, sham group participants were given the option to receive the TEA intervention over a period of 4 weeks.
transcutaneous electrical accustimulation at treatment point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit.
|
|---|---|---|---|
|
Cardiac disorders
Stroke
|
0.00%
0/21 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
5.0%
1/20 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
0.00%
0/13 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
|
Endocrine disorders
Diabetic Ketoacidosis
|
0.00%
0/21 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
5.0%
1/20 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
0.00%
0/13 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
|
Endocrine disorders
diabetic gastroparesis symptoms
|
4.8%
1/21 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
5.0%
1/20 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
0.00%
0/13 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
Other adverse events
| Measure |
Treatment Group
n=21 participants at risk
Subjects will be trained to use the devices at the treatment points and will undergo the treatment twice per day for 8 weeks. Following the first 8 weeks, at visit two, the devices will be collected by the study team.
transcutaneous electrical accustimulation at treatment point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Sham Group
n=20 participants at risk
Subjects will be trained to use the devices at sham points and will undergo sham stimulation for the first 8 weeks. At visit two, after unmasking, subjects will optionally be trained on the treatment points and may participate in treatment for 4 weeks.
transcutaneous electrical accustimulation at sham point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
|
Participants Who Received Open Label Treatment After Having Received Sham
n=13 participants at risk
Participants in this arm were randomized into the sham group arm for the 8-week trial period. Following the trial, sham group participants were given the option to receive the TEA intervention over a period of 4 weeks.
transcutaneous electrical accustimulation at treatment point.: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit.
|
|---|---|---|---|
|
Skin and subcutaneous tissue disorders
Skin Reactions
|
9.5%
2/21 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
5.0%
1/20 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
0.00%
0/13 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
|
Gastrointestinal disorders
Increased Bowel Movements
|
4.8%
1/21 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
0.00%
0/20 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
0.00%
0/13 • 8 weeks for "Treatment Group" and "Sham Group," and 4 weeks for "Participants Who Received Open Label Treatment After Having Received Sham"
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place